Dr. Jin-an Jiao

Advisor and Consultant

Dr. Jin-an Jiao, serves as a strategic advisor for SAB having been the company's CSO until 2017 where he oversaw product development, clinical studies and manufacturing. 

Prior to SAB, Dr. Jiao was Executive Vice President at Hematech Inc., a subsidiary of Kyowa Hakko Kirin Pharma, Inc (KKP), and was head of Antigen and Antibody Purification at Sanford Applied Biosciences from January 2013 to June 2014. He played a direct role in the design of several preclinical studies for both monoclonal and polyclonal antibody products. Dr. Jiao was also a key player in writing and editing four monoclonal INDs, and participated in multiple pre-IND and IND meetings with the FDA. In 1996, he joined Sunol Molecular Corp. to direct the R&D activities on thrombosis, cancer, inflammatory and infectious diseases, and successfully developed four monoclonal antibody products that were evaluated in human clinical trials.  

Dr. Jiao received his Ph.D. in Biochemistry from University of Nebraska-Lincoln in 1990. After his postdoctoral study at the University of California-Berkeley from 1991 to 1992, he worked as a group leader of protein biochemistry at Baxter Diagnostics, Miami, FL.  

P 605/679.6984
E jjiao@sabbiotherapeutics.com